Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Can-Fite Biopharma Ltd ADR (NY: CANF ) 2.150 UNCHANGED Streaming Delayed Price Updated: 8:00 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 2.150 Bid (Size) 2.160 (20) Ask (Size) 2.430 (20) Prev. Close 2.150 Today's Range 2.150 - 2.150 52wk Range 1.830 - 4.690 Shares Outstanding 515,746,293 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV August 09, 2024 Via ACCESSWIRE Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite’s Partner Vetbiolix June 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Performance YTD +3.86% +3.86% 1 Month +7.50% +7.50% 3 Month -21.25% -21.25% 6 Month +1.90% +1.90% 1 Year -0.23% -0.23% More News Read More Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver June 24, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can Fite Biofarma: Q4 Earnings Insights March 28, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session June 14, 2024 Via Benzinga Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 14, 2024 Via Benzinga Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study June 10, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study June 05, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases May 29, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 May 27, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on June 6 May 23, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study May 13, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV May 10, 2024 Via ACCESSWIRE Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study May 09, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602 May 06, 2024 From Can-Fite BioPharma Ltd. Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session April 25, 2024 Via Benzinga Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal April 25, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH April 15, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients April 03, 2024 From Can-Fite BioPharma Ltd. Via Business Wire CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023 March 28, 2024 Via InvestorPlace Can-Fite Reports 2023 Financial Results and Clinical Update March 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference March 11, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada February 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication January 30, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study January 29, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
